International Journal of Infertility & Fetal Medicine

Register      Login

VOLUME 6 , ISSUE 1 ( January-April, 2015 ) > List of Articles

REVIEW ARTICLE

Review on Antagonists

Divya Sardana

Citation Information : Sardana D. Review on Antagonists. Int J Infertil Fetal Med 2015; 6 (1):1-10.

DOI: 10.5005/jp-journals-10016-1093

License: CC BY-NC 4.0

Published Online: 01-04-2015

Copyright Statement:  Copyright © 2015; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

How to cite this article

Sardana D. Review on Antagonists. Int J Infertil Fetal Med 2015;6(1):1-10.


PDF Share
  1. Dose-finding study of triptorelin acetate for prevention of a premature LH surge in IVF: a prospective, randomized, double-blind, placebo-controlled study. Hum Reprod 2000;15(11):2333-2340.
  2. Ovulation induction protocols. Arch Pathol Lab Med 1992;116(4):406-409.
  3. Novel antagonists of GnRH: a compendium of their physicochemical properties, activities, relative potencies and efficacy in humans. In: Insler V, Lunenfeld B, editors. GnRH Analogues: The State of the Art 1993. 1st ed. New York, USA: The Parthenon Publishing Group; 1993. p. 13-26.
  4. Gonadotropin-releasing hormone analog design. Structure-function studies toward the development of agonists and antagonists: rationale and perspective. Endocr Rev 1986;7(1):44-66.
  5. Potent gonadotropin releasing hormone antagonists with low histamine-releasing activity. J Med Chem 1992;35(21):3942-3948.
  6. Embryo implantation and GnRH antagonists: GnRH antagonists do not activate the GnRH receptor. Hum Reprod 2000;15(9):1882-1883.
  7. Effect of the gonadotropin-releasing hormone antagonist ganirelix on cyclic adenosine monophosphate accumulation of human granulosa-lutein cells. Fertil Steril 2000;74(5):1001-1007.
  8. Embryo implantation and GnRH antagonists: ovarian actions of GnRH antagonists. Hum Reprod 2001;16(4):608-611.
  9. The use of a GnRH antagonist (Cetrorelix) in a single-dose protocol in IVF-embryo transfer: a dose finding study of 3 vs 2 mg. Hum Reprod 1998;13(9):2411-2414.
  10. The ganirelix dose-finding study group. Hum Reprod 1998;13(11):3023-3031.
  11. Tailoring the GnRH antagonist cetrorelix acetate to individual patients’ needs in ovarian stimulation for IVF: results of a prospective, randomized study. Hum Reprod 2002;17(11):2842-2845.
  12. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in vitro fertilization cycles: a pilot study. Hum Reprod 1995;10(6):1382-1386.
  13. Endocrine effects and pharmacokinetic characteristics of a potent new gonadotropin-releasing hormone antagonist (Ganirelix) with minimal histamine-releasing properties: studies in postmenopausal women. J Clin Endocrinol Metab 1992; 75(5):1220-1225.
  14. Pharmacodynamic effects and plasma pharmacokinetics of single-doses of cetrorelix acetate in healthy premenopausal women. Fertil Steril 2001; 75(2):316-323.
  15. Single and multiple dose pharmacokinetics and pharmacodynamics of the gonadotrophin-releasing hormone antagonist Cetrorelix in healthy female volunteers. Hum Reprod 1998;13(9):2392-2398.
  16. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/ Orgalutran). Part I. Absolute bioavailability of 0.25 mg of ganirelix after a single subcutaneous injection in healthy female volunteers. Fertil Steril 1999;72(6):1001-1005.
  17. Pharmacokinetic and pharmacodynamic characteristics of ganirelix (Antagon/ Orgalutran). Part II. Dose-proportionality and gonadotropin suppression after multiple doses of ganirelix in healthy female volunteers. Fertil Steril 1999;72(6):1006-1012.
  18. Ovarian stimulation with HMG: results of a prospective randomized phase III European study comparing the luteinizing hormonereleasing hormone (LHRH)-antagonist cetrorelix and the LHRH-agonist buserelin. European Cetrorelix Study Group. Hum Reprod 2000;15(3):526-531.
  19. Comparable clinical outcome using the GnRH antagonist ganirelix or a long protocol of the GnRH agonist triptorelin for the prevention of premature LH surges in women undergoing ovarian stimulation. Hum Reprod. Hum Reprod 2001;16(4): 644-651.
  20. Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to ‘friendly IVF’? Hum Reprod 2002;17(8): 2022-2026.
  21. Alternate day and daily administration of GnRH antagonist may prevent premature luteinization to a similar extent during FSH treatment. Hum Reprod 2005;20(11):3192-3197.
  22. Timing of HCG administration for ovulation triggering in GnRH antagonist cycles. A Randomized Controlled Trial. Hum Reprod 2003; 18:2.
  23. Prolongation of the follicular phase in in vitro fertilization results in a lower ongoing pregnancy rate in cycles stimulated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril 2004;82(1):102-107.
  24. Among patients treated for IVF with gonadotrophins and GnRH analogues, is the probability of live birth dependent on the type of analogue used? A systematic review and meta-analysis. Hum Reprod Update 2006;12(6):651-671.
  25. GnRH-antagonists in ovarian stimulation for IVF in patients with poor response to gonadotrophins, polycystic ovary syndrome, and risk of ovarian hyperstimulation: a meta-analysis. Reprod Biomed Online 2006;13(5):628-638.
  26. GnRH agonist for triggering final oocyte maturation in the GnRH antagonist ovarian hyperstimulation protocol: a systematic review and meta-analysis. Hum Reprod Update 2006;12(2):159-168.
  27. Cumulative live birth rates after GnRH-agonist triggering of final oocyte maturation in patients at risk of OHSS: a prospective, clinical cohort study. Eur J Obstet Gynecol Reprod Biol 2010;149(2):190-194.
  28. Gonadotropinreleasing hormone agonists versus antagonists for controlled ovarian hyperstimulation in oocyte donors: a systematic review and meta-analysis. Fertil Steril 2011;95(1):164-169.
  29. The luteal phase of nonsupplemented cycles after ovarian superovulation with human menopausal gonadotropin and the gonadotropinreleasing hormone antagonist Cetrorelix. Fertil Steril 1998; 70(2):357-359.
  30. Nonsupplemented luteal phase characteristics after the administration of recombinant human chorionic gonadotropin, recombinant luteinizing hormone, or gonadotropin-releasing hormone (GnRH) agonist to induce final oocyte maturation in in vitro fertilization patients after ovarian stimulation with recombinant follicle-stimulating hormone and GnRH antagonist cotreatment J Clin Endocrinol Metab 2003;88(9):4186-4192.
  31. Estrogen addition to progesterone for luteal phase support in cycles stimulated with GnRH analogues and gonadotropins for IVF: a systematic review and meta-analysis. Hum Reprod 2008;23(6):1346-1354.
  32. Elevated progesterone at initiation of stimulation is associated with a lower ongoing pregnancy rate after IVF using GnRH antagonists. Hum Reprod 2004;19(7):1525-1529.
  33. Scheduled administration of a gonadotrophin-releasing hormone antagonist (Cetrorelix) on day 8 of in vitro fertilization cycles: a pilot study. Hum Reprod 1995;10(6):1382-1386.
  34. Significantly lower pregnancy rates in the presence of progesterone elevation in patients treated with GnRH antagonists and gonadotrophins: a systematic review and meta-analysis. Curr Pharm Biotechnol 2012;13(3):464-470.
  35. Effect of ovarian stimulation with recombinant follicle-stimulating hormone, gonadotropin releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril 2002;78(5):1025-1029.
  36. Progesterone elevation and probability of pregnancy after IVF: a systematic review and meta-analysis of over 60000 cycles. Hum Reprod Update 2013;19(5):433-457.
  37. Endometrial receptivity is affected in women with high circulating progesterone levels at the end of the follicular phase: a functional genomics analysis. Hum Reprod 2011;26:1813-1825.
  38. MicroRNA array and microarray evaluation of endometrial receptivity in patients with high seum progesterone levels on the day of hCG administration. Reprod Biol Endocrinol 2011;9:29.
  39. Progesterone rise on hCG day in GnRH antagonist/ rFSH stimulated cycles affects endometrial gene expression. Reprod Biomed Online 2011;22:263-271.
  40. Suppression of the endogenous luteinizing hormone surge by the gonadotrophin-releasing hormone antagonist Cetrorelix during ovarian stimulation. Hum Reprod 1994;9(5):788-791.
  41. Ovarian stimulation for assisted reproduction with HMG and concomitant midcycle administration of the GnRH antagonist cetrorelix according to the multiple dose protocol: a prospective uncontrolled phase III study. Hum Reprod 2000;15(5):1015-1020.
  42. Treatment with the gonadotrophinreleasing hormone antagonist ganirelix in women undergoing ovarian stimulation with recombinant follicle stimulating hormone is effective, safe and convenient: results of a controlled, randomized, multicentre trial. The European Orgalutran Study Group. Hum Reprod 2000;15(7):1490-1498.
  43. Efficacy and safety of ganirelix acetate versus leuprolide acetate in women undergoing controlled ovarian hyperstimulation. Fertil Steril 2001;75(1):38-45.
  44. Embryo implantation and GnRH antagonists: embryo implantation: the Rubicon for GnRH antagonists. Hum Reprod 2000;15(6):1211-1216.
  45. Dynamics of the development of multiple follicles during ovarian stimulation for in vitro fertilization using recombinant follicle-stimulating hormone (Puregon) and various doses of the gonadotropin-releasing hormone antagonist ganirelix (Orgalutran/Antagon). Fertil Steril 2001;75(4):688-693.
  46. Gonadotropin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2011;5:CD001750.
  47. GnRH antagonists and endometrial receptivity in oocyte recipients: a prospective randomized trial. Reprod Biomed Online 2009;18(2):276-281.
  48. Health of 227 children born after controlled ovarian stimulation for in vitro fertilization using the luteinizing hormone-releasing hormone antagonist cetrorelix. Fertil Steril 2001;75(1):18-22.
  49. Gonadotropin-releasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2001;(4):CD001750.
  50. Gonadotropinreleasing hormone antagonists for assisted conception. Cochrane Database Syst Rev 2006;(3):CD001750.
  51. GnRH agonist versus GnRH antagonist in ovarian stimulation: an ongoing debate. Reprod Biomed Online 2013;26(1):4-8.
  52. Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration. Fertil Steril 2005;83(6):1700-1707.
  53. Prospective, randomized trial comparing cetrorelix acetate and ganirelix acetate in a programmed, flexible protocol for premature luteinizing hormone surge prevention in assisted reproductive technologies. Fertil Steril 2005;84(1):108-117.
  54. Optimizing GnRH antagonist administration: meta-analysis of fixed versus flexible protocol. Reprod Biomed Online 2005; 10(5):567-570.
  55. Gonadotropin-releasing hormone antagonist protocol: a novel method for ovarian stimulation in poor responders. Eur J Obstet Gynecol Reprod Biol 2001;97:202-207.
  56. Comparison of agonistic flare-up protocol and antagonistic multiple dose protocol in ovarian stimulation of poor responders: results of a prospective randomized trial. Hum Reprod 2001;16:868-870.
  57. Tailoring the GnRH antagonist cetrorelix acetate to individual patients’ needs in ovarian stimulation for IVF: results of a prospective, randomized study. Hum Reprod 2002;17:2842-2845.
  58. Fixed versus flexible gonadotropin – releasing hormone antagonist administration in in vitro fertilization: a randomized controlled trial. Fertil Steril 2011; 95:558-562.
  59. Comparison of two different starting multiple dose gonadotropin-releasing hormone antagonist protocols in a selected group of in vitro fertilization-embryo transfer patients. Fertil Steril 2004;81(3):562-566.
  60. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril 2003;79:873-880.
  61. Effect of ovarian stimulation with recombinant follicle stimulating hormone, gonadotropin-releasing hormone antagonists, and human chorionic gonadotropin on endometrial maturation on the day of oocyte pick-up. Fertil Steril 2002;78:1025-1029.
  62. A double-blind, non-inferiority RCT comparing corifollitropin alfa and recombinant FSH during the first 7 days of ovarian stimulation using a GnRH antagonist protocol. Hum Reprod 2009;24(12): 3063-3072.
  63. Reducing the incidence of weekend oocyte retrievals in a rFSH/GnRH-antagonist protocol by optimizing the start day of rFSH and delaying human chorionic gonadotropin (hCG) by 1 day. Fertil Steril 2011;95:s16.
  64. Oral contraceptive pretreatment significantly reduces ongoing pregnancy likelihood in gonadotropin-releasing hormone antagonist cycles: an updated meta-analysis. Fertil Steril 2010;94(6):2382-2384.
  65. A prospective, randomized comparison of two starting doses of recombinant FSH in combination with cetrorelix in women undergoing ovarian stimulation for IVF/ICSI. Hum Reprod 2001;16(8):1676-1681.
  66. A randomized, double-blind clinical trial using fixed daily doses of 100 or 200 IU of recombinant FSH in ICSI cycles. Hum Reprod 2001;16(6):1104-1109.
  67. A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for in vitro fertilization-embryo transfer. Fertil Steril 2006;86(1):58-63.
  68. Increasing the dose of human menopausal gonadotrophins on day of GnRH antagonist administration: randomized controlled trial. Reprod Biomed Online 2004;8(5):524-527.
  69. Meta-analysis of GnRH antagonist protocols: do they reduce the risk of OHSS in PCOS? Reprod Biomed Online 2012;24(1):6-22.
  70. GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. Hum Reprod 2005;20(3):616-621.
  71. Fine tuning cycle day 3 hormonal assessment of ovarian reserve improves in vitro fertilization outcome in gonadotropin-releasing hormone antagonist cycles. Fertil Steril 2003;80(5):1156-1161.
  72. Premenstrual administration of gonadotropin-releasing hormone antagonist coordinates early antral follicle sizes and sets up the basis for an innovative concept of controlled ovarian hyperstimulation. Fertil Steril 2004;81(6):1554-1559.
  73. Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle. Fertil Steril 2009;91(6):2437-2444.
  74. Gonadotropin-releasing hormone agonist/antagonist conversion with estrogen priming in low responders with prior in vitro fertilization failure. Fertil Steril 2008;89(2):342-347.
  75. Interventions for poor responders to controlled ovarian hyperstimulation (COH) in in vitro fertilization (IVF). Cochrane Database Syst Rev 2010;(1):CD004379.
  76. Addition of a gonadotropin releasing hormone (GnRH) antagonist and exogenous gonadotropins to unstimulated in vitro fertilization (IVF) cycles: physiologic observations and preliminary experience. J Assist Reprod Genet 1994;11(1):28-32.
  77. Minimal stimulation using gonadotropin-releasing hormone (GnRH) antagonist and recombinant human follicle-stimulating hormone versus GnRH antagonist multiple-dose protocol in low responders undergoing in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril 2009;92(6):2082-2084.
  78. The use of ovulation-inducing agents in in vitro fertilization. Clin Obstet Gynecol 1984;27(4):983-992.
  79. Relationship between luteinizing hormone and oestradiol in IVF cycles before GnRH antagonist initiation. Reprod BioMed Online 2003;7:190-193.
  80. Exposure to high levels of luteinizing hormone and estradiol in the early follicular phase of gonadotropin-releasing hormone antagonist cycles is associated with a reduced chance of pregnancy. Fertil Steril 2003;79:873-880.
  81. Administration of gonadotropin- releasing hormone antagonist from day 1 of stimulation in in vitro fertilization. Fertil Steril 2004;82(1):223-226.
  82. Management of severe OHSS using GnRH antagonists and blastocyst cryopreservation in PCOS patients treated with long protocol. Reprod Biomed Online 2009;18(1):15-20.
  83. Live births after management of severe OHSS by GnRH antagonist administration in the luteal phase. Reprod Biomed Online 2009;19(6):789-795.
  84. GnRH antagonist (cetrotide) instead of agonist to prepare recipients for embryo transfer: a prospective, randomized, controlled trial. Fertil Steril. 2008;90(Suppl):S384.
  85. Timing ovulation for intrauterine insemination with a GnRH antagonist. Hum Reprod 2005;20(2):368-372.
  86. Multifollicular recruitment in combination with gonadotropin-releasing hormone antagonist increased pregnancy rates in intrauterine insemination cycles. Fertil Steril 2008;89:620-624.
  87. Effects and clinical significance of GnRH antagonist administration for IUI timing in FSH superovulated cycles: a meta-analysis. Fertil Steril 2008;90: 367-372.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.